Astellas, Aveo Final Trial Of Kidney-Cancer Drug Said Better Than Nexavar
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and U.S.-based Aveo Oncology report that Phase III trial results of their tivozanib drug for treating advanced kidney cancer passed safety and tolerability tests.